Trial
NCT05193994
Triumeq in Amyotrophic Lateral Sclerosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Macquarie University, Australia
Collaborators
King's College London; Stichting TRICALS Foundation
Condition
Amyotrophic Lateral Sclerosis
Intervention
Dolutegravir, Abacavir and Lamivudine
Why stopped
A planned interim analysis resulted in the recommendation that the trial be stopped. The results showed no benefit of Triumeq for people with ALS compared with placebo on survival, the primary outcome measure.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-11